Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

The management of serous papillary uterine cancer

Schwartz, Peter E

doi: 10.1097/01.cco.0000239890.36408.75
Gynecologic cancer
Buy

Purpose of review Uterine papillary serous cancer is an extremely aggressive cancer, the optimum management of which is still being determined. It is important to understand advances that have been made in 2005 regarding the molecular biology, diagnosis, and management of this deadly disease.

Recent findings The main themes in the literature regarding uterine papillary serous cancer are that a potential precursor lesion, serous endometrial intraepithelial carcinoma, has been recognized as an early form of the disease. A variety of molecular biologically important markers have now been identified, including p53, HER2/neu, IL-6, kallikrein 6, and claudin-4, some of which may be susceptible to molecularly targeted therapy. Systematic surgical staging is necessary before additional therapy is recommended. Stage I uterine papillary serous cancer requires aggressive treatment, including surgery, chemotherapy, and radiation therapy for successful treatment. The most effective management of advanced stage disease remains to be resolved.

Summary Serous endometrial intraepithelial carcinoma should be treated as a form of uterine papillary serous cancer. Multimodality therapy is required for the successful management of early stage uterine papillary serous cancer. Advanced disease is often unresponsive to conventional therapy. Molecularly targeted therapies are now being introduced into the management of this disease.

Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, Connecticut, USA

Correspondence to Peter E. Schwartz, MD, Department of Obstetrics and Gynecology, Yale University School of Medicine, 333 Cedar Street – FMB 316, New Haven, CT 06510, USA Tel: +1 203 785 4014; fax: +1 203 785 4135; e-mail: peter.schwartz@yale.edu

© 2006 Lippincott Williams & Wilkins, Inc.